Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Time to secondary progres… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Artikel i vetenskaplig tidskrift
Författare Helen Tedeholm
Jan Lycke
Bengt Skoog
Vera Lisovskaja
J Hillert
C Dahle
J Fagius
S Fredrikson
A-M Landtblom
Clas Malmeström
C Martin
F Piehl
Björn Runmarker
L Stawiarz
M Vrethem
Olle Nerman
Oluf Andersen
Publicerad i Multiple Sclerosis Journal
Volym 19
Nummer/häfte 6
Sidor 765-774
ISSN 1477-0970
Publiceringsår 2013
Publicerad vid Institutionen för matematiska vetenskaper, matematisk statistik
Sidor 765-774
Språk en
Länkar dx.doi.org/10.1177/1352458512463764
https://gup.ub.gu.se/file/197292
Ämnesord multipel skleros, DMD, progression, RRMS, SPMS, bromsmedicin
Ämneskategorier Klinisk medicin

Sammanfattning

Background: It is currently unknown whether early immunomodulatory treatment in relapsing–remitting MS (RRMS) can delay the transition to secondary progression (SP).

Objective: To compare the time interval from onset to SP in patients with RRMS between a contemporary cohort, treated with first generation disease modifying drugs (DMDs), and a historical control cohort.

Methods: We included a cohort of contemporary RRMS patients treated with DMDs, obtained from the Swedish National MS Registry (disease onset between 1995–2004, n = 730) and a historical population-based incidence cohort (onset 1950–64, n = 186). We retrospectively analyzed the difference in time to SP, termed the “period effect” within a 12-year survival analysis, using Kaplan-Meier and Cox regression analysis.

Results: We found that the “period” affected the entire severity spectrum. After adjusting for onset features, which were weaker in the contemporary material, as well as the therapy initiation time, the DMD-treated patients still exhibited a longer time to SP than the controls (hazard ratios: men, 0.32; women, 0.53).

Conclusion: Our results showed there was a longer time to SP in the contemporary subjects given DMD. Our analyses suggested that this effect was not solely driven by the inclusion of benign cases, and it was at least partly due to the long-term immunomodulating therapy given

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?